Recent advances in immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and its ligand PD-L1, have considerably influenced cancer treatment [5, 6]. Here, PDCD1 is linked to cancer.